Chiron recalls measles vaccine
Morupar, a combination vaccine for mumps and rubella, had $10 million in sales last year.
NEW YORK (CNNMoney.com) - Chiron Corp. said Thursday that is recalling its Morupar vaccine for measles, mumps and rubella.
Chiron (unchanged at $45.70, Research), a California-based drug maker, said it provided 5 million doses of the treatment in 2005, mostly for developing countries, through the United Nations Children's Fund and Pan American Health Organization.
Chiron said it is recalling the vaccine after noticing adverse events, including fever, allergic reactions and swelling of the glands, during routine surveillance of inoculated patients in Italy. Chiron said the events do not affect long-term health.
The company said Morupar sales were $10 million in 2005, with overall company sales that year at $1.4 billion. Because of the recall, Chiron revised its 2005 income for continuing operations, decreasing earnings per share by three cents, to $1.31.
To read about Chiron's troubles with vaccine production, click here.